TCS foresees FY25 outperforming FY24, leveraging AI and cost optimization despite market volatility, BFSI challenges, and election impacts. With Q1 achievements, reduced attrition, strategic headcount growth, and strong India business, performance remains robust. Investments in talent, discretionary project validation, and technology adaptation sustain a healthy order book, even amid fewer mega deals and extended decision-making cycles.
Dr. Reddy’s Laboratories Q1 Results: PAT rises 2% YoY to Rs 1,418 crore, revenue jumps 11%
Dr Reddy’s Laboratories Q1 Results: Pharma major Dr. Reddy’s Laboratories reported a marginal 2% year-on-year (YoY) growth in its consolidated net profit at Rs 1,418
July 23, 2025